CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue Estimates

CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -125.00%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.06 per share when it actually produced break-even earnings, delivering a surprise of +100%.Over the last four qua ...